Thirty-three clinical posters focused on the role of the advanced practitioner were presented at JADPRO Live this past November 9 to 12, 2023, in Orlando, Florida. Read the abstracts here, and access the full posters and audio narrations...
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2021 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2021 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2021 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...
Nina N. Grenon, DNP, AGCNP-BC, AOCN®, of Dana-Farber Cancer Institute, evaluates data on single and dual immunotherapy for advanced esophageal squamous cell carcinoma; maintenance therapy for metastatic colorectal cancer; a HER2-targeted...
Morgane C. Diven, PharmD, BCOP, of Phoenix VA Health Care System, evaluates research on an investigational radiolabeled small molecule, combination therapy in the treatment of de novo metastatic prostate cancer, and a CYP17-lyase inhibit...
Following coverage from The ASCO Post, Emily Lemke, DNP, AGPCNP-BC, AOCNP®, of Medical College of Wisconsin Cancer Center, comments on an adjuvant trial of a checkpoint inhibitor for clear cell renal cell carcinoma (RCC), real-world data...
Laura Doherty, FNP-BC, AOCNP®, of Women & Infants Hospital of Rhode Island/Brown University, interprets data on adjuvant chemotherapy for locally advanced cervical cancer, bevacizumab for advanced ovarian cancer, a new treatment opti...
Abby Fuoto, DNP, ANP-BC, AOCNP®, ACHPN, of University of Arizona Cancer Center, considers the implications of a novel monoclonal antibody for nasopharyngeal cancer, and Mee-young Lee, MSN, ANP-BC, of Monter Cancer Center, Northwell, disc...
Amber B. Koehler, PA-C, MS, P. Andrew Allred, MS, PA-C, and Donna Catamero, ANP-BC, OCN®, CCRC
With conference reporting provided by The ASCO Post, Amber B. Koehler, PA-C, MS, of Mayo Clinic, evaluates data on BTK inhibitors; fixed-duration, first-line treatment with ibrutinib plus venetoclax; and a novel oral BCL2 antagonist for ...
Josh Epworth, ARNP, of University of Washington Medical Center, considers the findings of three important abstracts from the 2021 ASCO Annual Meeting and reflects on how advanced practitioners can improve access and care for their patien...
Amy Pierre, MSN, ANP-BC, of Flatiron Health and Memorial Sloan Kettering Cancer Center, considers takeaways from a program targeting minority accrual to oncology trials and a study evaluating minority representation in precision oncology...
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, reviews important research in thoracic cancers presented at the 2021 ASCO Annual Meeting, including atezolizumab in early-stage lung cancer, the addition of doubl...
With coverage from The ASCO Post, Lisa Kottschade, APRN, MSN, CNP, of Mayo Clinic, reviews data on immune therapy after surgery, the combination of the anti–LAG-3 antibody relatlimab and nivolumab, and a 6.5-year update of combination ni...
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2020 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2020 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2020 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2019 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2019 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...
Presented by Robert Dreicer, MD, MS, MACP, FASCO, and Morgane C. Diven, PharmD, BCOP
Robert Dreicer, MD, MS, MACP, FASCO, and Morgane C. Diven, PharmD, BCOP, discussed the emerging data regarding the role of genomics in metastatic castration-sensitive and -resistant prostate cancer, as well as strategies to manage the to...
Abstracts from JADPRO Live 2019
Washington State Convention Center • Seattle • October 24–27
The posters for the abstracts below can be found at: eventscribe.com/2019/posters/JADPROLIVE/home.asp.
Abstracts from JADPRO Live 2018
THE DIPLOMAT HOTEL, HOLLYWOOD, FLORIDA • NOVEMBER 1–4, 2018
The posters for the abstracts below can be found at eventscribe.com/2018/posters/JADPROLIVE/home.asp.
Advanced practitioners can play an important role in assessing patients with myeloid malignancies for fitness and addressing vulnerabilities so that patients can benefit from allogeneic stem cell transplant, which remains the best option...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Background: Advanced practice providers...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Context: Iron chelation therapy for i...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Introduction: Relapsed and/or refractor...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Objective: This was a descriptive stu...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Background: Providing care to hematolog...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Background: Adverse drug reactions ar...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
outstanding Poster Award
Backgroun...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Background: Health-care providers have ...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Context: A metabolic emergency related ...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Objective: Current guidelines recomme...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Background: The predicted oncology/he...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Background: The complex care and ma...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Background: The Center for Medicare S...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Background: With continuous advanceme...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
JL516. Management of Cytokine Relea...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Background: As advanced practice prov...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Introduction: Soft tissue sarcoma (...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
Background: Daratumumab (dara) is a CD38 targeting monoclonal antibody with significant activity in multiple myeloma. Infusion-related reacti...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Objective/Background: The Center for ...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Purpose/Objectives: To determine th...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Objective: Providing survivorship car...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Objective: The Centers for Disease Co...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Background: Comprehensive cancer care...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
JL525. Real-World Systemic Therapy ...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Background: Rituximab is a monoclonal...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Background: Telemedicine has been des...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Background: Aurora Health Care (AHC) ...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Background: Rituximab (Rituxan), an a...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Background: Located in Houston’s Texa...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Purpose: To present an overview of th...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Purposes/Aims: The purpose of this st...
Abstracts From JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017
The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp
Purpose: To implement and evaluate an...
Background: Lung cancer is often diagnosed late when treatment options are limited. The goal of screening for lung cancer with low dose CT is to diagnose at an earlier stage, when more treatment options including potentially curative sur...
Introduction: Previous studies have alluded to the beneficial effects of vitamin D, particularly with regard to cancer. Vitamin D has been suggested to decrease negative effects of cancer treatments, hinder growth of tumor cells and redu...
Objective: Our cancer infusion room treats sixty patients per day. Infusions include complex chemotherapy, monoclonal antibodies, and research pharmaceuticals. The high volume of infusions and the complexity of the regimens has led to in...
Aim: To highlight an academic cancer center’s approach to providing comprehensive care by utilizing a short-stay outpatient observation unit. Background: The Clinical Decision Unit (CDU) is a 16 bed observation unit that focuses on probl...
Purpose: To develop and evaluate the use of a comprehensive educational checklist for allogeneic stem cell transplant patients, that will be used by all members of the HSCT interdisciplinary team (IDT) during initial transplant hospitali...
Purpose: To increase awareness and promote understanding of multidisciplinary care for breast cancer patients. Background: Clinical rotations are designed to bridge the gap between didactic and practice. However, there are significant va...
Background: Phlebotomy is often used to maintain hematocrit < 45% and prevent thrombotic events in patients with polycythemia vera (PV); however, phlebotomy procedures are inconvenient and/or poorly tolerated by some patients. Iron de...
Background: Venous thromboembolism (VTE) is a highly prevalent complication in patients with cancer with reported incidence rates ranging between 8-19% (Khorana, Dalal, Lin, & Connolly, 2013). Patients with VTE have at least a 2-fold...
Objective: Gastrointestinal toxicity (GIT) is associated with targeted therapies in cancer treatment. GIT can lead to diminished treatment adherence and poor quality of life. It is among the top causes of emergency room visits and hospit...
Introduction/Background: In recent years, the treatment paradigm for management of advanced pancreatic cancer has changed dramatically. Because oncology nurses are on the front line of care for patients with pancreatic cancer, we sought ...
Background: The incidence of influenza in hematopoietic stem cell recipients is 7-35% with a 15-35% mortality rate (Shah et al., 2012). Vinograd et al. (2014) reported a 48% compliance rate in influenza vaccinations. In our NCI-designate...
Background: Combination therapy with nivolumab (NIVO) and ipilimumab (IPI) is approved for the first-line treatment of advanced melanoma (MEL). Recent phase 1 studies have also shown promising efficacy with NIVO+IPI in patients (pts) wit...
Background: Nivolumab (NIVO) and ipilimumab (IPI) combination therapy is approved for the first-line treatment of advanced melanoma (MEL), and recent phase 1 studies have shown promising efficacy in non-small cell lung cancer (NSCLC) and...
Introduction: HCC is the fifth most common malignant neoplasm in men and ninth most common in women worldwide. Although the incidence of HCC in the United States is rare, the incidence of this particular cancer is rising secondary to the...
Objective: Breast cancer survivors are highly motivated to make lifestyle changes that enhance health (Urquhart, 2010). Nurses and nurse practitioners (NPs) often provide cancer survivor care and are in an influential position to educate...
Introduction: Parathyroid carcinoma is a rare malignancy that can be difficult to diagnose due to clinical features shared with benign primary hyperparathyroidism (PHPT). It accounts for 1% of PHPT cases and has symptoms commonly referre...
Background: Performance improvement (PI) is one of the newest CME learning formats designed for providers to evaluate and make changes to their clinical practice. In 2014, The National Commission on Certification of Physician Assistants ...
Purpose: The purpose of this poster presentation is to educate advanced hematology/oncology practitioners how to diagnose, evaluate thrombotic risk, manage and treat patients with primary polycythemia vera. Background: Primary polycythem...
Background: The contributions of advance practice providers (APPs) to an oncology practice are complex, and it can be challenging to discern and measure how their unique contributions are impacting their practice. Two terms, productivity...
Background: The Universal Patient Language (UPL), is a set of resources developed by Bristol-Myers Squibb, to help communicate with patients about complex topics. At the core of the UPL are seven foundational principles. BMS applied thes...
According to the Oncology Nursing Society (ONS), part of the advanced practice nurse (APN) role is to provide genetic and genomic care to individuals in conjunction with expert providers (ONS, 2012). This is a review of a genetic risk as...
Patients with metastatic lung cancer experience high levels of distress due to their disease trajectory and treatment. Oncology nurses are experts in patient care and symptom management giving them the opportunity to screen and treat pat...
Introduction: Soft tissue sarcoma (STS) is cancer of connective tissues and comprises a collection of over 50 distinct diagnoses. Approximately 11,000 cases are diagnosed in the US each year, accounting for about 1% of all adult cancers....
Objective: The purpose of this descriptive correlational study was to examine how the number of medications taken on a daily basis by elderly Chronic Lymphocytic Leukemia (CLL) patients is related to their functional status and quality o...
Objective: Tumor lysis syndrome (TLS) refers to the constellation of metabolic disturbances that may follow the initiation of cancer treatment. It can occur in patients with bulky, rapidly proliferating, treatment-responsive tumors such ...
Background: The Oncology Nurse Practitioner Web Education Resource (ONc-PoWER) is an online course developed by Margaret Rosenzweig, PhD, FNP-BC, AOCNP® from the University of Pittsburgh School of Nursing and funded by the National Cance...
Background: Mild-to-moderate bone pain is the most commonly reported adverse event (AE) associated with pegfilgrastim. Anecdotal reports and some studies have suggested that naproxen (an NSAID) and loratadine (an antihistamine) may help ...
Background: Around 30–50% of ALK+ NSCLC patients have brain metastases (BM) before initiating ALK inhibitor (ALKi) treatment. In general, the prognosis for patients with BM is poor (median survival 7 months). Standard treatments include ...
Background: The decision to prescribe a packed red blood cell (PRBC) transfusion in patients with chemotherapy-induced anemia includes assessment of clinical features such as the patient’s cancer type and treatment regimen, severity of s...
There has been an increase in the development of oral cancer agents in recent years. This has created a paradigm shift in the management of the adult oncology/hematology population as patients must assume increased responsibility for und...
Oncology patient visits are anticipated to increase annually as the population ages with an estimated 24,540 new cancer diagnoses in Colorado in 2015. This year, University of Colorado Anschutz Cancer Pavilion (ACP) visits have increased...
Background: Advanced practice nurses (APRNs) caring for prostate cancer patients in a community setting noted that bone health was not being monitored in patients receiving ADT. A review of published articles in early 2011 revealed littl...
Background: The Oncology Nurse Practitioner Web Education Resource (ONc-PoWER) is an online course developed by Margaret Rosenzweig, PhD, FNP-BC, AOCNP, from the University of Pittsburgh School of Nursing and funded by the National Cance...
As professionals, we pride ourselves on delivering high quality care. However, until five years ago, there was no method of demonstrating a practice’s level of excellence distinction from competing practices. In 2010, the Quality Oncolog...
Scope of Problem: Understanding care needs across the cancer trajectory requires sensitive communication about diagnosis, discussing factors influencing treatment decision-making, mediating family communication, and psychosocial counseli...
Objective: There is a knowledge gap between the capabilities of advocacy groups and healthcare providers (HCPs) and patients. The need to create awareness about valuable resources, available through not-for-profit organizations, for HCPs...
Introduction/Purpose: Utilization of established cancer screening guidelines ensures recommendations that are individualized to a patient’s level of risk. The purpose of this survey was to understand how APRNs in Texas access and utilize...
Peer Review is the evaluation of professionals by a peer who practices in a similar role and scope of practice. Yale New Haven Hospital (YNHH) Medical Staff Office utilizes ‘The Joint Commission’ ongoing professional practice evaluation ...
Background: Over 220,000 patients are diagnosed with lung cancer each year. Although only 15% are diagnosed at an early stage, with the possibility of curative surgery, this population numbers over 165,000 annual survivors. The purpose o...
Introduction: Targeted therapies for the treatment of metastatic NSCLC are associated with a distinct set of adverse side effects that differ clinically from those seen with chemotherapies. Our institution has been actively involved in c...
Introduction: Earlier this year, nivolumab, a fully human IgG4 anti–programmed death-1 (PD-1) immune checkpoint inhibitor antibody, gained approval for advanced-stage squamous-cell lung cancer in patients whose disease progressed after t...
Introduction/Background: Because multiple myeloma (MM) typically occurs in patients over 70 years of age, many patients present with comorbidities. This can present a challenge for the care team who must consider multiple factors which p...
Introduction: Multiple Myeloma (MM) treatment is undergoing rapid transformation. New agents and regimens create an increased need to proactively screen for, assess, and manage patient reported symptoms and concerns. The Carevive Care Pl...
Introduction: Significant changes to the multiple myeloma (MM) landscape have occurred within the past 10 years. Keeping up-to-date on drugs to treat MM and the management of side effects is challenging. The 2014 Multiple Myeloma Mentors...
Background: The Advanced Practitioner Society for Hematology and Oncology (APSHO) conducted a survey of its members over a 6 week period in the summer of 2014 to describe practice patterns. Significance of the Problem: Cancer survivors a...
Background: MDS represent a heterogeneous group of myeloid malignancies with variable prognosis. MDS are underdiagnosed, and many lower-risk patients are offered only supportive care (Khan AM. Am J Med. 2012;125[7 suppl]:S15-S7). This st...
Introduction: Oral mucositis refers to the damage of the mouth’s mucosa resulting from chemotherapy or radiation therapy. It is one of the most significantly debilitating, dose-limiting acute toxicities of cancer therapy that not only co...
Introduction: The advent of immune checkpoint inhibitors has substantially improved the treatment of advanced melanoma in the past 5 years. Ipilimumab was the first drug to prolong overall survival, while nivolumab and pembrolizumab have...
Introduction: Much of oncology care is now delivered through a team approach; understanding the potential benefits of the physician/APP collaborative unit, in addition to the value of the APP individually, has never been more important. ...
Advanced practice nurses have played a vital role in progressing and enhancing clinical practice. They have collaborated with many disciplines, including, but not limited to, medicine, biology, sociology, and psychology. These collaborat...
Introduction: Ipilimumab and nivolumab are immune checkpoint inhibitors approved for advanced melanoma. According to clinical trials, combination of these agents has greater efficacy compared with monotherapy. However, both nivolumab and...
Background: Dermatologic adverse events (dAE) can occur during and after all anticancer treatment regimens such as, but not limited to, rashes, nail abnormalities hand and feet symptoms, alopecia, xerosis, pruritus, radiation dermatitis,...
Integration of a first-in-class drug into clinical practice generates a need for information to support its safe and effective use. In the early days post-FDA approval, the amount of available information can be limited and knowing how t...
System and patient-based barriers lead to the inability of individuals to access appropriate treatment and oncologic care. Establishment of a homebound hematopoietic stem cell transplantation (HSCT) program promotes increased access to c...
Background and Specific Aims: As healthcare institutions transition to value-based payment systems, there is an increasing need to identify the true costs of delivering health services. The costing methodology Time-Driven Activity-Based ...
Introduction: A decade ago the Institute of Medicine recommended that every survivor receive a survivor care plan (SCP) yet despite endorsements of clinical merit, evidence is still evolving regarding SCP utility and value to patients. M...
Novel immune checkpoint inhibitors are changing the treatment options for advanced melanoma. Advanced practitioners may be familiar with ipilimumab, which inhibits the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) pathway. The nex...
Hypercalcemia is a common paraneoplastic syndrome associated with a variety of malignancies including lymphomas, aerodigestive, uterine, endometrial, breast, neuroendocrine, cervical, and renal cell carcinomas. The incidence of hypercalc...
Objective: To examine the efficacy of a transdermal granisetron patch for controlling CINV in head and neck cancer patients. Significance: Head and neck cancer patients can experience mechanical obstruction or dysphagia making adherence ...
Objective: To review published data on the metabolism of toremifene and assess any implications for treatment decisions. Significance: The use of selective estrogen receptor modulators (SERMs) forms part of the treatment backbone of horm...
Background: Nurse practitioners (NP) new to cancer care are entering practice without any standardized oncology curriculum. This gap in knowledge can lead to poor patient outcomes, risk management vulnerabilities, and high clinician attr...
Background: The Research Decision Making Model guided this completed research on decision making for cancer clinical trial participation. The Research Decision Model was based on Bowling and Ebrahim’s Model for Treatment Decision Making ...
There are several names given across the United States for the orders that direct end of care life. In some states, it is called Medical Orders for Life Sustaining Treatment (MOLST), in other states, Provider (or Physician) Orders for Li...
Purpose: The purpose of this poster presentation is to educate advanced practice professionals regarding vaccinations post hematopoietic stem cell transplantation and to focus on the standardization and implementation of vaccinations pos...
In the United States more women are diagnosed with breast cancer than any other type of cancer. As survival for these women improve health care practitioners must address long-term problems secondary to cancer therapy. The development of...
Programmed death-1 (PD-1) immune checkpoint inhibitors are novel immuno-oncology agents being developed for the treatment of advanced non-small cell lung cancer (NSCLC) and other cancers. Clinical trial data have shown promising antitumo...
The optimal evaluation and management of the patient with gastrointestinal (GI) malignancy is multimodal, involving coordination between multiple specialties, including radiology, pathology, medical oncology, surgical oncology, radiation...
Purpose: The purpose of this randomized controlled study is to determine the clinical feasibility of using virtual reality at the bedside with patients who are undergoing a bone marrow biopsy. Outcome measures included pre and post pain ...
Significance: Holistic medicine, as defined by the American Holistic Medical Association, “is the art and science of healing that addresses care of the whole person—body, mind, and spirit.” The practice of holistic medicine integrates co...
Background: Endocrine therapy is an integral part of the backbone for hormone receptor–positive breast cancer treatment. Toremifene and tamoxifen are approved for hormone receptor–positive metastatic breast cancer. Tamoxifen is also appr...
Background: Chemotherapy-induced nausea and vomiting (CINV) is a common side effect of multiday chemotherapy that can lead to poor adherence, decreased quality of life, and compromised functional status. Commonly used routes of administr...
Background: Hereditary hemochromatosis is a disorder in which excessive iron absorption occurs, leading to an increase in iron deposits in major organs of the body and resulting in end organ damage. This is the most common genetic disord...
Treatment of meningeal carcinomatosis among breast cancer patients remains a clinical challenge, with a dismal outlook for long-term survival. Intrathecal thiotepa administration has been described in the literature; however, there are p...
Background: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine cutaneous malignancy with an atypical presentation, associated with the merkel cell polyomavirus (MCPyV) in 80% to 90% of cases. The vowel mnemonic, AEIOU is represe...
Breast cancer is a biologically complex disease and remains one of the leading causes of cancer-related deaths in the world. Recent advances in genomic profiling of breast cancer tumors show promise in improving the outcomes of breast ca...
Background: The subcutaneous (SC) route of administration for bortezomib was approved in the United States in January 2012 in addition to the intravenous (IV) route. Although there is limited guidance in the US Prescribing Information r...
The Oncology Nursing Society’s 2009–2013 research agenda highlights the need for greater attention to impaired physical functioning in inpatients with cancer because of the significant physical, psychological, and economic consequences. ...
Lenalidomide (LEN) is an oral immunomodulatory medication approved for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1‒risk myelodysplastic syndromes (MDS) with del(5q). In clinical trials of LEN...
Lenalidomide (LEN) is an oral immunomodulatory medication approved for patients with lower-risk, transfusion-dependent myelodysplastic syndromes (MDS) with del(5q) with or without additional cytogenetic abnormalities. The goal of LEN tre...
Over 10,000 individuals are diagnosed with myelodysplastic syndromes (MDS) annually in the United States. Bone marrow (BM) examination is essential for diagnosis, classification, and risk-stratification of MDS. The World Health Organizat...
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2019 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...
Introduction
The collaborative practice model is well known to improve patient care and enhance health-care delivery. Many different scenarios of collaborative practice have been described in the literature, often combining the teamwork...
